Quantcast

Latest Tyrosine kinase inhibitors Stories

2010-11-20 00:00:47

Results from Phase II biomarker analysis of erlotinib in combination with sorafenib presented at Molecular Targets in Cancer Therapeutic meeting in Berlin, Germany. Broomfield, CO (Vocus) November 19, 2010 Results from the VeriStrat analysis of a phase II trial of first line erlotinib in combination with sorafenib in patients with advanced non-small cell lung cancer (NSCLC) were presented today at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets in Cancer Therapeutics being held in...

2010-11-19 06:55:00

NEW YORK, Nov. 19, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced today that the Phase 3 AXIS 1032 trial (A4061032), studying the investigational compound axitinib in previously treated patients with metastatic renal cell carcinoma (mRCC), has met its primary endpoint, demonstrating that axitinib significantly extended progression-free survival (PFS) when compared to sorafenib, in the study population. Consistent with previous analyses, axitinib demonstrated a generally...

2010-11-17 13:41:47

Scientists believe they may have found a new target for treating triple negative breast cancer "“ one of the more difficult breast cancers to treat successfully and for which there is no targeted therapy at present. Triple negative breast cancer (TNBC) is a cancer that does not express receptors for oestrogen (ER), progesterone (PR) or the human epidermal growth factor (HER2). It tends to be more aggressive, occurs more often in younger women, and is difficult to treat successfully as...

2010-11-10 12:17:00

BROOMFIELD, Colo., Nov. 10, 2010 /PRNewswire/ -- Biodesix Inc. announced today that the company has raised $7.1 million in new equity financing, lead by existing investors. The Series C round, which included 5 new investors, will support ongoing commercialization activities for the company's first product VeriStrat®, a serum proteomic test that helps physicians guide treatment for patients with non-small cell lung cancer (NSCLC). Existing shareholders of the company...

2010-11-10 06:00:00

BEIJING, Nov. 10, 2010 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based advanced in-vitro diagnostic ("IVD") company, today announced that it has received approval for its real-time PCR-based Epidermal Growth Factor Receptor ("EGFR") Assay (the "EGFR PCR Assay") for the use of lung cancer targeted drugs from the State Food and Drug Administration of China (the "SFDA"). The EGFR PCR Assay is used for the detection of the...

2010-10-28 11:44:00

Patients with rare type of leukemia now have another treatment option SILVER SPRING, Md., Oct. 28 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved a new indication for Sprycel (dasatinib) for the treatment of a rare blood cancer when it is first diagnosed. The cancer, called Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph+ CP-CML), is a slowly progressing blood and bone marrow disease linked to a genetic abnormality. (Logo:...

2010-10-12 18:07:56

New data reported at the 35th ESMO Congress A new-generation lung cancer drug has shown an impressive ability to prevent disease progression when administered as a first-line treatment in patients with advanced disease, investigators reported at the 35th Congress of the European Society for Medical Oncology (ESMO). Preliminary results from an ongoing Phase-II trial of the drug PF299804 (PF-299) showed that close to 85% of patients whose cancers harbor mutated forms of the EGFR gene have...

2010-10-12 17:58:41

Lung cancer patients who have already been treated with the EGFR inhibitors erlotinib or gefitinib seem to gain further benefits in terms of progression-free survival and tumor shrinkage when treated with the new drug afatinib, the results of a Phase IIb/III trial show. At the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy, Dr Vincent Miller from Memorial Sloan-Kettering Cancer Center in New York, USA, reported findings from the LUX-Lung 1 trial of afatinib...

2010-10-11 13:42:01

A subset of lung cancer patients seem to live longer and experience delays in disease progression when a new drug that targets a cancer-associated molecule called MET is added to treatment with erlotinib, the results of a double-blind Phase-II trial show. Dr David Spigel, Director of lung cancer research for the Sarah Cannon Research Institute in Nashville, Tennessee reported the trial findings at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy. The study...

2010-10-11 13:19:53

Phase-III data presented at 35th ESMO Congress For patients with advanced lung cancer whose tumors carry EGFR activating mutations, first-line treatment with erlotinib nearly tripled progression-free survival compared to a standard chemotherapy combination, show results from the first prospective Phase-III study to report findings in this setting. The new results from the OPTIMAL trial were reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy....


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related